MX2017005807A - Inmunoterapia especifica de multipeptidos t terapeuticos para el tratamiento de metastasis cerebrales. - Google Patents
Inmunoterapia especifica de multipeptidos t terapeuticos para el tratamiento de metastasis cerebrales.Info
- Publication number
- MX2017005807A MX2017005807A MX2017005807A MX2017005807A MX2017005807A MX 2017005807 A MX2017005807 A MX 2017005807A MX 2017005807 A MX2017005807 A MX 2017005807A MX 2017005807 A MX2017005807 A MX 2017005807A MX 2017005807 A MX2017005807 A MX 2017005807A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- multipeptides
- terapeutic
- specific immunotherapy
- cerebral metastasis
- Prior art date
Links
- 206010027476 Metastases Diseases 0.000 title 1
- 230000002490 cerebral effect Effects 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 230000009401 metastasis Effects 0.000 title 1
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 abstract 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 abstract 1
- 206010059282 Metastases to central nervous system Diseases 0.000 abstract 1
- 229940023041 peptide vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una composición de vacuna de péptidos OSE-2101 para el tratamiento de metástasis cerebrales en pacientes positivos para HLA-A2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2014/073975 WO2016070928A1 (en) | 2014-11-06 | 2014-11-06 | Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017005807A true MX2017005807A (es) | 2017-08-02 |
| MX386458B MX386458B (es) | 2025-03-18 |
Family
ID=51871025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017005807A MX386458B (es) | 2014-11-06 | 2014-11-06 | Composiciones de péptidos t inmuno-terapéuticas para usarse en el tratamiento de metástasis cerebrales. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10434157B2 (es) |
| EP (1) | EP3215184B1 (es) |
| JP (1) | JP6474893B2 (es) |
| KR (1) | KR102043725B1 (es) |
| CN (1) | CN107073087B (es) |
| AR (1) | AR102555A1 (es) |
| AU (1) | AU2014410466B2 (es) |
| BR (1) | BR112017009358A2 (es) |
| CA (1) | CA2963184C (es) |
| EA (1) | EA037271B1 (es) |
| ES (1) | ES2874006T3 (es) |
| IL (1) | IL250576B (es) |
| MX (1) | MX386458B (es) |
| NZ (1) | NZ729514A (es) |
| TW (1) | TWI703982B (es) |
| WO (1) | WO2016070928A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL255722B2 (en) * | 2015-06-29 | 2024-05-01 | Ose Immunotherapeutics | A method for inducing an early memory response with an anticancer vaccine of short peptides |
| PL4029494T3 (pl) * | 2017-01-25 | 2026-03-23 | Ose Immunotherapeutics | Sposób wytwarzania stabilnej emulsji do dostarczania peptydów |
| NZ765655A (en) * | 2017-11-27 | 2026-01-30 | Ose Immunotherapeutics | Improved treatment of cancer |
| CN109988748A (zh) * | 2017-12-29 | 2019-07-09 | 深圳华大生命科学研究院 | 一种从til筛选肿瘤特异性t细胞的方法 |
| ES2963700T3 (es) | 2018-12-21 | 2024-04-01 | Ose Immunotherapeutics | Anticuerpo humanizado anti-PD-1 humana |
| WO2025093541A1 (en) | 2023-10-31 | 2025-05-08 | Ose Immunotherapeutics | Combination of interleukin 7 and tumour associated antigen vaccine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1620456E (pt) * | 2003-04-18 | 2014-04-15 | Biotech Synergy Inc | Péptidos antigénicos hla-a2 associados a tumor e suas composições |
| RU2408605C2 (ru) * | 2005-02-18 | 2011-01-10 | Анджиокем Инк. | Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат |
| RS53782B1 (sr) * | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera |
| CN103145803B (zh) * | 2012-12-13 | 2014-03-12 | 东南大学 | 一种与乳腺癌脑转移细胞特异性结合的多肽 |
-
2014
- 2014-11-06 JP JP2017518779A patent/JP6474893B2/ja active Active
- 2014-11-06 CN CN201480082351.XA patent/CN107073087B/zh active Active
- 2014-11-06 CA CA2963184A patent/CA2963184C/en active Active
- 2014-11-06 NZ NZ729514A patent/NZ729514A/en unknown
- 2014-11-06 EA EA201790990A patent/EA037271B1/ru unknown
- 2014-11-06 AU AU2014410466A patent/AU2014410466B2/en active Active
- 2014-11-06 EP EP14796049.6A patent/EP3215184B1/en active Active
- 2014-11-06 WO PCT/EP2014/073975 patent/WO2016070928A1/en not_active Ceased
- 2014-11-06 ES ES14796049T patent/ES2874006T3/es active Active
- 2014-11-06 US US15/524,278 patent/US10434157B2/en active Active
- 2014-11-06 KR KR1020177015327A patent/KR102043725B1/ko active Active
- 2014-11-06 MX MX2017005807A patent/MX386458B/es unknown
- 2014-11-06 BR BR112017009358A patent/BR112017009358A2/pt not_active Application Discontinuation
-
2015
- 2015-10-27 TW TW104135282A patent/TWI703982B/zh active
- 2015-11-05 AR ARP150103601A patent/AR102555A1/es unknown
-
2017
- 2017-02-13 IL IL250576A patent/IL250576B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017009358A2 (pt) | 2017-12-19 |
| WO2016070928A1 (en) | 2016-05-12 |
| US10434157B2 (en) | 2019-10-08 |
| EP3215184A1 (en) | 2017-09-13 |
| EA037271B1 (ru) | 2021-03-02 |
| US20170319672A1 (en) | 2017-11-09 |
| MX386458B (es) | 2025-03-18 |
| EP3215184B1 (en) | 2021-03-03 |
| IL250576A0 (en) | 2017-03-30 |
| CA2963184A1 (en) | 2016-05-12 |
| AU2014410466B2 (en) | 2019-09-12 |
| IL250576B (en) | 2019-09-26 |
| AU2014410466A1 (en) | 2017-03-30 |
| NZ729514A (en) | 2019-12-20 |
| KR102043725B1 (ko) | 2019-11-13 |
| TW201625287A (zh) | 2016-07-16 |
| CN107073087B (zh) | 2020-09-08 |
| CN107073087A (zh) | 2017-08-18 |
| KR20170098811A (ko) | 2017-08-30 |
| CA2963184C (en) | 2020-11-24 |
| ES2874006T3 (es) | 2021-11-04 |
| EA201790990A1 (ru) | 2017-09-29 |
| JP6474893B2 (ja) | 2019-02-27 |
| TWI703982B (zh) | 2020-09-11 |
| JP2017533898A (ja) | 2017-11-16 |
| AR102555A1 (es) | 2017-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| IL251890A0 (en) | Combination immunotherapy approach for treatment of cancer | |
| EA201791310A1 (ru) | Химерные антигенные рецепторы к bcma | |
| SV2016005267A (es) | Terapias de combinación con anticuerpos anti-cd38 | |
| EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
| EA201691974A1 (ru) | Антитела против ox40 и способы их применения | |
| BR112016028891A2 (pt) | processos de trens de sementes e usos dos mesmos | |
| PE20171094A1 (es) | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda | |
| GEAP202114450A (en) | Anti-tigit antibodies | |
| BR112016019871A2 (pt) | anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda | |
| EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
| IL247857A0 (en) | Dynamic enablement of several processes at the same time | |
| MX377534B (es) | Compuestos para usarse en el tratamiento de hiperinsulinemia. | |
| MX2017005807A (es) | Inmunoterapia especifica de multipeptidos t terapeuticos para el tratamiento de metastasis cerebrales. | |
| DK2897382T3 (da) | Forbedring af binaural kilde | |
| CL2017000087A1 (es) | Un proceso novedoso para la purificación de rhu-gcsf | |
| PT3215132T (pt) | Amantadina para melhorar a marcha em esclerose múltipla | |
| BR112016019389A8 (pt) | Vacina, e, peptídeo | |
| DK3578179T3 (da) | Process for the preparation of cyclic depsipeptides | |
| DE112015002229A5 (de) | Formulierungen zur Behandlung von Hyperthyreose | |
| MX382659B (es) | Proceso para la preparación de derivados de tiazol. | |
| MX2016015623A (es) | Proceso para la preparacion de derivados dihidroisoxazol. | |
| RU2014154366A (ru) | Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний | |
| DOP2017000001A (es) | Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer | |
| GEAP201814327A (en) | Treatment regimen tiacumicin compound |